Vaccine Design and Testing – News and Features

Goal of the trial is to establish safety and immune activity of DPX-Survivac in ovarian cancer patients.

The goal of the Phase I clinical trial is to establish the safety and immune activity of therapeutic cancer vaccine DPX-Survivac in patients with ovarian cancer.

The company announced that CPL Biologics (CPLB), its joint venture in India with Cadila Pharmaceuticals Ltd., has made significant progress with its vaccine-development programs in 2011 and is preparing to initiate clinical studies of vaccine candidates to prevent influenza and rabies in 2012 and 2013, respectively.

NIH scientists developed experimental vaccine.

The Swiss-German biotech firm and Merck KGaA spin-off, have announced the start of the first clinical trial of its investigational oral therapeutic cancer vaccine VXM01.

United States Patent and Trademark Office has issued two patents to VIRxSYS.

Collaboration validates, diversifies and further strengthens CureVac’s RNActive® technology platform.

Professors Jiri Mestecky, Willem van Eden and Peter J. Openshaw appointed to Scientific Advisory Board.

Midatech Ltd announced it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

NIH-supported group exploring whether protection extends to Nipah virus disease.